AstraZeneca bags Imfinzi okay in big Chinese lung cancer marketChina has approved AstraZeneca’s PD-1/PD-L1 inhibitor Imfinzi to treat small-cell lung cancer (SCLC), an aggressive form of the Share XAstraZeneca bags Imfinzi okay in big Chinese lung cancer markethttps://pharmaphorum.com/news/astrazeneca-bags-imfinzi-okay-in-big-chinese-lung-cancer-market/
AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLCAstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a Share XAZ, HutchMed’s savolitinib gets 1st approval in China for NSCLChttps://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/
Country focus: China & APAC’s growing medical needs bring opportunities and challengesDr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma Share XCountry focus: China & APAC’s growing medical needs bring opportunities and challengeshttps://pharmaphorum.com/oncology/country-focus-china-apacs-growing-medical-needs-bring-opportunities-and-challenges/
Nine for 2021: Addressing the pandemic legacyIn this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact Share XNine for 2021: Addressing the pandemic legacyhttps://pharmaphorum.com/views-analysis-sales-marketing/nine-for-2021-pandemic-legacy/
Sanofi preps trials of second COVID-19 shot, as Russia approves anotherSanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after Share XSanofi preps trials of second COVID-19 shot, as Russia approves anotherhttps://pharmaphorum.com/news/sanofi-preps-trials-of-second-covid-19-shot-as-russia-approves-another/
China starts vaccinating key workers against COVID-19; reportChina has already granted emergency use authorisation to multiple COVID-19 vaccines developed by domestic drugmakers and started dosing Share XChina starts vaccinating key workers against COVID-19; reporthttps://pharmaphorum.com/news/chinese-starts-vaccinating-key-workers-against-covid-19-report/
Bayer slides on €9.5bn loss caused by litigation, COVID-19 impactBayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion Share XBayer slides on €9.5bn loss caused by litigation, COVID-19 impacthttps://pharmaphorum.com/news/bayer-slides-on-e9-5bn-loss-caused-by-litigation-covid-19-impact/
BI opens second branch of digital lab in ChinaBoehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in Share XBI opens second branch of digital lab in Chinahttps://pharmaphorum.com/news/bi-opens-branch-of-digital-lab-in-china/
Does pharma’s future lie in China?Healthcare innovation has a long history in effective collaboration, whether that’s across academia and industry or borders. Some Share XDoes pharma’s future lie in China?https://pharmaphorum.com/r-d/views-analysis-r-d/does-pharmas-future-lie-in-china/
